Business
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1
About this update from Aptorum Group Limited
[{"type":"text","content":"NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online. The presentations will highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration.","length":694,"tagName":"p"},{"type":"text","content":"Details of the presentations include:","length":37,"tagName":"p"},{"type":"text","content":"Session. Clinical trials: Biomarkers, including plasma","length":54,"tagName":"p"},{"type":"text","content":"Date/Time. Wednesday, December 3rd, 2025; 7:15 A.M. – 5:30 P.M. PST","length":67,"tagName":"p"},{"type":"text","content":"Venue. Hilton San Diego Bayfront, San Diego, CA","length":47,"tagName":"p"},{"type":"text","content":"Poster #225: Developing microRNA classifiers enriched in brain and associated with inflammation in plasma samples to classify Cognitively Unimpaired, MCI, and AD study participants. This work was conducted in collaboration with the New York University (NYU) Alzheimer’s Disease Research Center (ADRC) and NYU ADRC’s grant #P30AG066512 contributed to supporting patient recruitment for the study.","length":395,"tagName":"p"},{"type":"text","content":"Poster #240: Characterization of stages of neurodegeneration using circulating brain-enriched and inflammation associated microRNAs. This work was conducted in collaboration with the University of Pennsylvania Alzheimer’s Disease Research Center.","length":246,"tagName":"p"},{"type":"text","content":"The studies were funded by the Small Business Innovation Research (SBIR) Grant #R44AG044860 from the National Institute on Aging (NIA) of the National Institutes of Health.","length":172,"tagName":"p"},{"type":"text","content":"About CTAD","length":10,"tagName":"p"},{"type":"text","content":"The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, has become a cornerstone event in Alzheimer’s disease (AD) clinica...